Disease Landscape and Forecast Insights

Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (…

According to Clarivate Epidemiology, there are approximately 4 million prevalent cases of Alzheimer’s disease (AD) and nearly 2.5 million prevalent cases of mild cognitive impairment (MCI) due to…

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate…

The Alzheimer’s disease (AD) market comprises a handful of symptomatic treatment options that offer modest efficacy for a limited duration, leaving clear opportunity for more-effective…

In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of Alzheimer’s Disease (AD), rendering it the first potential DMT…

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…

For the 3.8 million people in the United States with Alzheimer’s disease (AD) dementia, approved pharmacotherapy is limited to only modestly effective procognitive symptomatic agents (e.g.,…

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine)…

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease…

No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…

Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…